Jasper Therapeutics, Inc.
JSPRNASDAQHealthcareBiotechnology
Regular session
$0.6819
−$0.0341 · -4.76%
JSPR company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
44
Fair Value
Momentum
25
Weakening
Sentiment
57
Mixed
Risk resilience
10
Extreme Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteJasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Jeetinder Singh Mahal
- Listed since
- Jan 10, 2020
- Employees
- 22
Market position
Day range
Current $0.6819
52-week range
Current $0.6819
- Open
- $0.7047
- Previous close
- $0.716
- Volume
- 115.77K
- 0.1× average
- Average volume
- 1.16M
- Average daily volume
- Market cap
- 11.08M USD
- Beta
- 3.03
- Market reference 1
- 50-day average
- $0.6241
- +9.26% above average
- 200-day average
- $1.1364
- -39.99% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 7.62M USD
- P/E (TTM)
- -0.43×
- P/B (TTM)
- 13.85×
- P/S (TTM)
- 0×
- EV / EBITDA
- -0.1×
- Earnings yield
- -216.09%
- Free cash flow yield
- -219.99%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -1826.09%
- Return on assets
- -211.86%
- Return on invested capital
- -338.11%
Financial health
- Debt / equity
- 0.19×
- Current ratio
- 2.62×
- Altman Z-score
- -45.86
- Piotroski F-score
- 0 of 9
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 1.06M USD | — | — | — | — |
| Gross profit | −1.06M USD | — | — | — | — |
| Research and development | 60.52M USD | 55.82M USD | 51.79M USD | 34.63M USD | 25.42M USD |
| Selling, general, and administrative | 18.94M USD | 20.42M USD | 17.08M USD | 16.57M USD | 11.41M USD |
| Operating expenses | 79.46M USD | 76.24M USD | 68.86M USD | 51.2M USD | 36.83M USD |
| Interest income | 1.74M USD | 5.06M USD | 5.2M USD | 701K USD | — |
| Depreciation and amortization | 1.06M USD | 1.37M USD | 1.11M USD | 975K USD | 377K USD |
| Operating income | −80.52M USD | −76.24M USD | −68.86M USD | −51.2M USD | −36.83M USD |
| Net income | −75.8M USD | −71.27M USD | −64.47M USD | −37.69M USD | −30.64M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 55%
- 6 beats, 5 misses, 0 met estimates
- Average EPS surprise
- +12.10%
- 11 comparable reports
- Latest EPS result
- -0.1
- Estimate -0.27 · Beat by 62.66%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
JSPR peers
ETFs holding JSPR
Funds reporting this stock among their holdings, ordered by reported position size.
Continue in GoAI
Research JSPRresearch.disclaimer